From RTTNews:

BioNTech SE projects total company revenues of approximately 3 billion euros for financial year 2024, driven by the COVID-19 vaccine franchise and cost sharing structure with Pfizer Inc. With 17.5 billion euros in cash and investments, the company aims to maintain financial strength and generate significant interest income in 2024, planning for further growth in 2025.

In addition to the COVID-19 vaccine, BioNTech plans to drive revenue from oncology and respiratory combination vaccine launches in the coming years, pending successful development and regulatory approval. The company is currently conducting late-stage trials in multiple oncology indications and aims to have ten or more potentially registrational trials in their pipeline by the end of 2024.

Detailed full year 2024 financial guidance will be provided during the full year and fourth quarter 2023 financial results call on March 20, 2024. For more information, visit rttnews.com for earnings news, calendar, and stocks updates. For comments and feedback, contact [email protected].



Read more: BioNTech Issues 2024 Revenue Guidance